Published in J Infect Dis on January 31, 2011
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Global control of hepatitis C: where challenge meets opportunity. Nat Med (2013) 2.22
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors. Drug Alcohol Depend (2011) 1.22
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
The longitudinal association between homelessness, injection drug use, and injection-related risk behavior among persons with a history of injection drug use in Baltimore, MD. Drug Alcohol Depend (2013) 1.03
Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis (2011) 0.95
Reduction in HCV incidence among injection drug users attending needle and syringe programs in Australia: a linkage study. Am J Public Health (2013) 0.95
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. World J Gastroenterol (2013) 0.93
Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012. PLoS One (2014) 0.91
Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam. Eur J Gastroenterol Hepatol (2015) 0.90
Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis (2014) 0.90
Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis (2013) 0.87
Public health clinic-based hepatitis C testing and linkage to care in baltimore. J Viral Hepat (2016) 0.86
Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection. Am J Addict (2013) 0.85
Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav (2011) 0.84
Hepatitis C virus infection trends in Italy. Hepat Mon (2012) 0.83
Resilience among IDUs: planning strategies to help injection drug users to protect themselves and others from HIV/HCV infections. Subst Use Misuse (2012) 0.82
Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States. Infect Dis Rep (2011) 0.81
Senior Center-Based Hepatitis C Screening in Baltimore. Open Forum Infect Dis (2016) 0.81
A time since onset of injection model for hepatitis C spread amongst injecting drug users. J Math Biol (2012) 0.80
Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. J Clin Microbiol (2015) 0.79
Intravenous Drug Users Can Achieve a High Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon (2011) 0.78
Integrating health and prevention services in syringe access programs: a strategy to address unmet needs in a high-risk population. Public Health Rep (2014) 0.78
Hepatitis C virus-specific immune responses in noninjecting drug users. J Viral Hepat (2012) 0.78
Hepatitis C virus infection is not an independent risk factor for obstructive lung disease. COPD (2013) 0.78
Utilizing mHealth methods to identify patterns of high risk illicit drug use. Drug Alcohol Depend (2015) 0.77
An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy (2015) 0.77
Hepatitis C Virus Disease Progression in People Who Inject Drugs: Protocol for a Systematic Review and Meta-Analysis. JMIR Res Protoc (2015) 0.76
Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing. J Virol (2015) 0.76
Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections. J Clin Microbiol (2016) 0.75
Recovering Infectious HIV from Novel Syringe-Needle Combinations with Low Dead Space Volumes. AIDS Res Hum Retroviruses (2016) 0.75
Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era. J Community Med Health Educ (2016) 0.75
Drug users in Amsterdam: are they still at risk for HIV? PLoS One (2013) 0.75
The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Syst Rev (2016) 0.75
Experiences of Oxford House Residents Living with the Hepatitis C Virus. Front Psychol Behav Sci (2013) 0.75
The association between neighborhood residential rehabilitation and injection drug use in Baltimore, Maryland, 2000-2011. Health Place (2014) 0.75
Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC(3) Study. J Viral Hepat (2016) 0.75
Parallel declines in HIV and hepatitis C virus prevalence, but not in herpes simplex virus type 2 infection: A 10-year, serial cross-sectional study in an inner-city emergency department. J Clin Virol (2016) 0.75
Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest Connecticut. Drug Alcohol Rev (2016) 0.75
Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening. J Community Med Health Educ (2016) 0.75
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med (2004) 7.67
The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA (2000) 7.65
The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr (1991) 7.05
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health (1996) 5.45
HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS (1994) 3.67
Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy (2007) 3.52
Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology (2004) 3.47
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction (2007) 3.08
Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS (2005) 2.91
HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic. Am J Public Health (2000) 2.74
HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health (2005) 2.62
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998. Am J Epidemiol (2002) 2.29
Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol (2008) 2.27
Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health (2000) 2.09
Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995. Med J Aust (1997) 2.03
Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol (2003) 1.82
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat (2009) 1.69
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
HIV-associated behaviors among injecting-drug users--23 Cities, United States, May 2005-February 2006. MMWR Morb Mortal Wkly Rep (2009) 1.52
HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). J Acquir Immune Defic Syndr (2006) 1.49
HIV and AIDS--United States, 1981-2000. MMWR Morb Mortal Wkly Rep (2001) 1.48
Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug Alcohol Depend (2008) 1.41
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS (1998) 1.37
Trends in risk behavior and HIV seroprevalence in heterosexual injection drug users in San Francisco, 1986-1992. J Acquir Immune Defic Syndr (1994) 1.33
Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.30
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction (2009) 1.30
Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis (2006) 1.23
Seroprevalence stable and seroconversions rare among injection drug users in Los Angeles. J Acquir Immune Defic Syndr (1992) 1.21
Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged 18-30 years, 1994-2004. J Urban Health (2007) 1.21
Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scand J Infect Dis (2001) 1.03
Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat (2011) 1.02
A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users. Harm Reduct J (2006) 1.01
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Diagnosis, management, and treatment of hepatitis C. Hepatology (2004) 11.62
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med (2002) 10.07
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
The social structural production of HIV risk among injecting drug users. Soc Sci Med (2005) 7.78
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis (2004) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse (2002) 5.65
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet (2002) 5.60
The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21
Exceeding the limits of liver histology markers. J Hepatol (2008) 5.06
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A (2006) 4.54
Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis (2009) 4.33
Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25
The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev (2005) 4.09
Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry (2002) 4.07
Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. Subst Use Misuse (2006) 4.01
Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol (2003) 3.93
Structural and environmental barriers to condom use negotiation with clients among female sex workers: implications for HIV-prevention strategies and policy. Am J Public Health (2009) 3.85
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend (2005) 3.67
A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS (2007) 3.58
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence. J Urban Health (2006) 3.51
Prevalence and correlates of HIV infection among female sex workers in 2 Mexico-US border cities. J Infect Dis (2008) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45
The social epidemiology of substance use. Epidemiol Rev (2004) 3.41
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36
Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Rationale for evaluating North America's first medically supervised safer-injecting facility. Lancet Infect Dis (2004) 3.20
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep (2002) 3.14
Evaluation of an intervention to increase screening colonoscopy in an urban public hospital setting. J Urban Health (2006) 3.10
Occult hepatitis B. Lancet Infect Dis (2002) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Estimated numbers of men and women infected with HIV/AIDS in Tijuana, Mexico. J Urban Health (2006) 3.04
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Urban health: evidence, challenges, and directions. Annu Rev Public Health (2005) 3.02
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97
Club drugs as causal risk factors for HIV acquisition among men who have sex with men: a review. Subst Use Misuse (2006) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med (2005) 2.75
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Hepatitis C in the HIV-Infected Person. Ann Intern Med (2003) 2.67
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis (2009) 2.62
Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis (2010) 2.62
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Mental health service and medication use in New York City after the September 11, 2001, terrorist attack. Psychiatr Serv (2004) 2.58
Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS (2002) 2.57
Needlestick transmission of hepatitis C. JAMA (2002) 2.55
Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS (2002) 2.54
Cities and population health. Soc Sci Med (2005) 2.53
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology (2005) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect (2008) 2.49
Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav (2008) 2.49
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction (2008) 2.46
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clin Infect Dis (2008) 2.44
What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol (2007) 2.39